Decision Resources: More patients switch to Onglyza from Merck's Type 2 diabetes drugs

BURLINGTON, Mass. Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug from Merck’s Januvia (sitagliptin) and Janumet (sitagliptin and metformin), according to a new report by market research firm Decision Resources.


The report found that 9.3% of patients for whom Onglyza –– made by Bristol-Myers Squibb and AstraZeneca –– was not their first Type 2 diabetes drug had previously used Januvia, while 7.9% had used Janumet. All three drugs belong to the same class, known as DPP-IV inhibitors.



“While about half of physicians we surveyed predict their prescribing of Onglyza will increase over the next two years, and Onglyza has picked up some patient share from Januvia and Janumet, Januvia’s more favorable formulary positioning and noncoverage of Onglyza will remain important hurdles for Onglyza’s uptake,” Decision Resources analyst Kate Sullivan said.


Login or Register to post a comment.